An observational study to investigate patient-reported satisfaction with apixaban when switched from warfarin in Japanese NVAF patients (AGAIN study)

Not Applicable

• Conditions: on-valvular atrial fibrillation

• Registration Number: JPRN-UMIN000018970
• Lead Sponsor: Pfizer Japan Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-09-11
• Study Completion: 2016-12-25
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 865

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients whose warfarin is switched to apixaban at the timing of invasive procedures other than catheter ablation for treatment of AF. 2.Patients with a history of hypersensitivity to the active substance (apixaban) or to any of the excipients of this drug 3.Patients with clinically significant active bleeding. (judged by a physician in charge of the patients) 4.Patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk. (judged by a physician in charge of the patients) 5.Patients with renal failure (creatinine clearance <15 mL/min) (No clinical experience) 6.Patients who are not able to answer to the questionnaires.

Study & Design

• Study Type: Observational
• Study Design: Not specified